Yuasa Norihiro, Nimura Yuji
Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
Langenbecks Arch Surg. 2005 Aug;390(4):286-93. doi: 10.1007/s00423-004-0482-y. Epub 2004 Apr 30.
Early gastric cancer (EGC) is well accepted as having a favorable prognosis after surgical treatment. Difference in treatment strategies for EGC between Japan and western countries indicates a need for current information to be evaluated with regard to long-term survival rates of EGC patients throughout the world. To analyze survival rates and recurrence after resection of EGC, we investigated 51 reports in English that each included more than 50 cases of EGC treated by gastrectomy and had been published during the past 12 years (1992-2003). Prevalence of EGC among all gastric cancers was 45%-51% in Japan, but only 7%-28% in western countries. Mean age at diagnosis was less than 60 years in Japan and Korea, but was more than 60 in most of the Western countries. Actuarial and disease-specific 5-year survival rates for EGC were 72%-95.8% and 88%-98.3%, respectively. Those for EGC that were invading the submucosal layer were 71.6%-94.1% and 82%-96.6%, respectively. Those for EGC with lymph node metastasis were 57%-89.1% and 72%-93.5%, respectively. Prevalence of recurrence ranged from 1.0% to 13.8%. Larger clinical series with more EGC cases showed a lower prevalence of recurrence (P=0.531, P=0.0026). Liver and blood-borne distant metastasis represented the predominant pattern of relapse, accounting for over half (54%). Local recurrence and peritoneal dissemination represented 20% and 18% of all recurrences, respectively. Clinicopathological studies have shown lymph node metastasis to be closely related to depth of invasion, size of lesion, histological type, presence of ulcer or ulcer scar, and vessel involvement. Information on these factors is the key to successful treatment of EGC. When sufficient information has been assessed preoperatively, surgeons can select patients for whom less-invasive surgery should not increase the risk of recurrence.
早期胃癌(EGC)经手术治疗后预后良好已被广泛认可。日本与西方国家在EGC治疗策略上的差异表明,有必要依据全球EGC患者的长期生存率来评估当前信息。为分析EGC切除术后的生存率及复发情况,我们调查了51篇英文报告,这些报告均包含50多例接受胃切除术治疗的EGC病例,且均发表于过去12年(1992 - 2003年)。在日本,EGC在所有胃癌中的患病率为45% - 51%,而在西方国家仅为7% - 28%。在日本和韩国,EGC确诊时的平均年龄小于60岁,但在大多数西方国家则超过60岁。EGC的精算5年生存率和疾病特异性5年生存率分别为72% - 95.8%和88% - 98.3%。侵犯黏膜下层的EGC的相应生存率分别为71.6% - 94.1%和82% - 96.6%。有淋巴结转移的EGC的相应生存率分别为57% - 89.1%和72% - 93.5%。复发率在1.0%至13.8%之间。纳入更多EGC病例的更大规模临床系列研究显示复发率较低(P = 0.531,P = 0.0026)。肝转移和血行远处转移是主要的复发模式,占比超过一半(54%)。局部复发和腹膜播散分别占所有复发的20%和18%。临床病理研究表明,淋巴结转移与浸润深度、病变大小、组织学类型、溃疡或溃疡瘢痕的存在以及血管受累密切相关。这些因素的信息是成功治疗EGC的关键。术前评估足够信息后,外科医生可以选择那些实施微创性手术不会增加复发风险的患者。